CN101932572A - 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 - Google Patents

2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 Download PDF

Info

Publication number
CN101932572A
CN101932572A CN2009801018616A CN200980101861A CN101932572A CN 101932572 A CN101932572 A CN 101932572A CN 2009801018616 A CN2009801018616 A CN 2009801018616A CN 200980101861 A CN200980101861 A CN 200980101861A CN 101932572 A CN101932572 A CN 101932572A
Authority
CN
China
Prior art keywords
compound
inhibitors
compounds
cancer
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801018616A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·富利
R·D·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40404013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101932572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck and Co Inc filed Critical Merck Sharp and Dohme Ltd
Priority to CN201610345956.4A priority Critical patent/CN106008460B/zh
Publication of CN101932572A publication Critical patent/CN101932572A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CN2009801018616A 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 Pending CN101932572A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610345956.4A CN106008460B (zh) 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1033308P 2008-01-08 2008-01-08
US61/010333 2008-01-08
PCT/GB2009/000041 WO2009087381A1 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610345956.4A Division CN106008460B (zh) 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐

Publications (1)

Publication Number Publication Date
CN101932572A true CN101932572A (zh) 2010-12-29

Family

ID=40404013

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801018616A Pending CN101932572A (zh) 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
CN201610345956.4A Active CN106008460B (zh) 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610345956.4A Active CN106008460B (zh) 2008-01-08 2009-01-08 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐

Country Status (16)

Country Link
US (1) US8436185B2 (cg-RX-API-DMAC7.html)
EP (1) EP2240466B1 (cg-RX-API-DMAC7.html)
JP (1) JP5989965B2 (cg-RX-API-DMAC7.html)
KR (1) KR101653548B1 (cg-RX-API-DMAC7.html)
CN (2) CN101932572A (cg-RX-API-DMAC7.html)
AU (1) AU2009203598B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0906020A2 (cg-RX-API-DMAC7.html)
CA (1) CA2711491C (cg-RX-API-DMAC7.html)
ES (1) ES2548131T3 (cg-RX-API-DMAC7.html)
FR (1) FR18C1020I2 (cg-RX-API-DMAC7.html)
IL (1) IL206201A (cg-RX-API-DMAC7.html)
MX (1) MX337421B (cg-RX-API-DMAC7.html)
NL (1) NL300938I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ586675A (cg-RX-API-DMAC7.html)
WO (1) WO2009087381A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003902B (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018228474A1 (zh) * 2017-06-14 2018-12-20 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CN110300587A (zh) * 2017-04-04 2019-10-01 康姆芘法思催化剂股份有限公司 氘代(s)-2-(4-(哌啶-3-基)苯基)-2h-吲唑-7-甲酰胺
CN110709083A (zh) * 2017-03-27 2020-01-17 特沙诺有限公司 尼拉帕尼制剂
CN111065922A (zh) * 2017-09-13 2020-04-24 B.R.A.H.M.S有限公司 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
CN111094986A (zh) * 2017-09-13 2020-05-01 B.R.A.H.M.S有限公司 基于肾上腺髓质素前体的指导流体治疗的方法
CN111094981A (zh) * 2017-09-13 2020-05-01 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN119707921A (zh) * 2024-12-19 2025-03-28 四川轻化工大学 一种尼拉帕尼的合成方法
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
WO2017056498A1 (ja) * 2015-09-30 2017-04-06 国立大学法人東北大学 糖尿病性腎症の判定マーカー
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
CN107663190B (zh) * 2016-07-29 2020-06-09 钟桂发 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110049777A (zh) 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
AU2018246214B2 (en) * 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EA201992430A1 (ru) 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TWI791519B (zh) 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) * 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
EP3668857B1 (en) 2017-08-14 2023-07-05 Teva Pharmaceuticals International GmbH Processes for the preparation of niraparib and intermediates thereof
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) * 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN113166071B (zh) * 2018-10-03 2025-03-21 特沙诺有限公司 尼拉帕利盐
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110407704B (zh) * 2019-08-19 2022-05-17 常州沃腾化工科技有限公司 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法
JP7353474B2 (ja) 2019-09-24 2023-09-29 上海美悦生物科技発展有限公司 Irak阻害剤、その製造方法及び用途
JP2023524794A (ja) 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
JP2025506402A (ja) 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ.ベー. 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
JP2026517228A (ja) 2023-05-17 2026-05-28 テサロ, インコーポレイテッド がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用
WO2025027138A1 (en) 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
DK0841924T3 (da) 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
WO2000026193A1 (de) 1998-10-30 2000-05-11 Lonza Ag Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 2−フェニルベンズイミダゾールおよび2−フェニルインドール、その製造方法ならびに使用
DK1133477T3 (da) 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6508365B1 (en) * 1999-12-28 2003-01-21 Pitney Bowes Inc. Method of removing mail from a mailstream using an incoming mail sorting apparatus
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JPWO2004014861A1 (ja) 2002-08-09 2005-12-02 杏林製薬株式会社 4−置換キノリン−8−カルボン酸アミド誘導体とその薬理上許容される付加塩
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AU2004259741A1 (en) * 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
WO2005066136A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
CA2580833C (en) 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
JP5162465B2 (ja) 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
MX2008014004A (es) 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US7892667B2 (en) * 2006-09-13 2011-02-22 Altek Corporation Battery security device
BRPI0806245B1 (pt) * 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
JP2008228154A (ja) * 2007-03-15 2008-09-25 Fujitsu Ltd 表示装置,および遠隔操作装置

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709083A (zh) * 2017-03-27 2020-01-17 特沙诺有限公司 尼拉帕尼制剂
CN110300587A (zh) * 2017-04-04 2019-10-01 康姆芘法思催化剂股份有限公司 氘代(s)-2-(4-(哌啶-3-基)苯基)-2h-吲唑-7-甲酰胺
CN110300587B (zh) * 2017-04-04 2023-07-18 康姆芘法思催化剂股份有限公司 氘代(s)-2-(4-(哌啶-3-基)苯基)-2h-吲唑-7-甲酰胺
US11072596B2 (en) 2017-06-14 2021-07-27 Selection Bioscience Llc Poly(ADP-ribose) polymerase inhibitor, preparation method and use
WO2018228474A1 (zh) * 2017-06-14 2018-12-20 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CN111094986B (zh) * 2017-09-13 2023-11-10 B.R.A.H.M.S有限公司 基于肾上腺髓质素前体的指导流体治疗的方法
CN111094981A (zh) * 2017-09-13 2020-05-01 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
CN111094986A (zh) * 2017-09-13 2020-05-01 B.R.A.H.M.S有限公司 基于肾上腺髓质素前体的指导流体治疗的方法
CN111065922A (zh) * 2017-09-13 2020-04-24 B.R.A.H.M.S有限公司 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
CN111094981B (zh) * 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CN119707921A (zh) * 2024-12-19 2025-03-28 四川轻化工大学 一种尼拉帕尼的合成方法
CN119707921B (zh) * 2024-12-19 2026-03-03 四川轻化工大学 一种尼拉帕尼的合成方法

Also Published As

Publication number Publication date
FR18C1020I2 (fr) 2019-06-07
MX2010006593A (es) 2010-12-21
FR18C1020I1 (cg-RX-API-DMAC7.html) 2018-07-13
CA2711491C (en) 2016-03-08
WO2009087381A1 (en) 2009-07-16
KR101653548B1 (ko) 2016-09-02
ZA201003902B (en) 2011-02-23
JP2011509252A (ja) 2011-03-24
EP2240466A1 (en) 2010-10-20
EP2240466B1 (en) 2015-07-29
RU2010133241A (ru) 2012-02-20
NL300938I2 (nl) 2019-01-08
RU2495035C2 (ru) 2013-10-10
US8436185B2 (en) 2013-05-07
US20100286203A1 (en) 2010-11-11
MX337421B (es) 2016-03-04
CN106008460B (zh) 2022-08-12
CA2711491A1 (en) 2009-07-16
KR20100114021A (ko) 2010-10-22
NZ586675A (en) 2012-04-27
CN106008460A (zh) 2016-10-12
AU2009203598A1 (en) 2009-07-16
IL206201A (en) 2014-07-31
IL206201A0 (en) 2010-12-30
AU2009203598B2 (en) 2013-09-26
ES2548131T3 (es) 2015-10-14
JP5989965B2 (ja) 2016-09-07
BRPI0906020A2 (pt) 2015-06-30

Similar Documents

Publication Publication Date Title
US8436185B2 (en) Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8071623B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
TWI528961B (zh) 作為聚(adp-核糖)聚合酶(parp)抑制劑之經醯胺取代之吲唑
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121102

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Hertfordshire

Applicant after: MERCK SHARP & DOHME LTD.

Applicant after: MERCK SHARP & DOHME Corp.

Address before: Hertfordshire

Applicant before: MERCK SHARP & DOHME LTD.

Applicant before: SCHERING Corp.

Address after: Hertfordshire

Applicant after: MERCK SHARP & DOHME LTD.

Applicant after: MERCK SHARP & DOHME Corp.

Address before: Hertfordshire

Applicant before: MERCK SHARP & DOHME LTD.

Applicant before: MERCK & Co.,Inc.

TA01 Transfer of patent application right

Effective date of registration: 20121102

Address after: Hertfordshire

Applicant after: MERCK SHARP & DOHME LTD.

Applicant after: SCHERING Corp.

Address before: Hertfordshire

Applicant before: MERCK SHARP & DOHME LTD.

Applicant before: MERCK SHARP & DOHME Corp.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101229